You just read:

US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer's Xeljanz, Roche/Genentech's Actemra, and Sanofi/Regeneron's Recently Launched Kevzara

News provided by

Spherix Global Insights

Oct 23, 2017, 10:34 ET